High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions

Blood

Volumn 97, Issue 9, 2001, Pages 2574-2579

  Badros, Ashraf ^a,b   Barlogie, Bart ^a   Morris, Christopher ^a   Desikan, Raman ^a   Martin, Sara R ^a   Munshi, Nikhil ^a   Zangari, Maurizio ^a   Toor, Amir ^a   Cottler Fox, Michele ^a   Fassas, Athanasios ^a   Aniassie, Elie ^a   Schichman, Steven ^a   Tricot, Guido ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; AMPHOTERICIN B LIPID COMPLEX; CD4 ANTIGEN; CD8 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; ITRACONAZOLE; LEVOFLOXACIN; MELPHALAN; THALIDOMIDE;

ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; LEUKAPHERESIS; LYMPHOCYTE; MALE; MORTALITY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; REMISSION; RISK; STEM CELL TRANSPLANTATION; SURVIVAL; VIRUS INFECTION;

EID: 0035353184     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.9.2574     Document Type: Article

References (23)

1. Desikan R, Barlogie B, Sawyer J, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood. 2000;95:4008-4010.
2. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol. 1995;13:1312-1322.
3. Cavo M, Benni M, Cirio TM, GozzettiA, Tura S. Allogeneic bone marrow transplantation for the treatment of multiple myeloma. An overview of published reports. Stem Cells. 1995;13(suppl 2):126-131.
4. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood. 1996;88:2787-2793.
5. Bensinger WI, Buckner D, Gahrton G. Allogeneic stem cell transplantation for multiple myeloma. Hematol Oncol Clin North Am. 1997;11:147-157.
6. Majolino I, Corradini P, Scime R, et al. Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant. 1998;22:449-455.
7. Gahrton G. Allogeneic bone marrow transplantation in multiple myeloma. Pathol Biol. 1999;47:188-191.
8. Bjorkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996;88:4711-4718.
9. Martinelli G, Terragna C, Zamagni E, et al. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation. Haematologica. 2000;85:930-934.
10. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000;18:3031-3037.
11. Orsini E, Alyea EP, Schlossman R, et al. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant. 2000;25:623-632.
12. Dazzi F, Goldman J. Donor lymphocyte infusions. Curr Opin Hematol. 1999;6:394-399.
13. Helg C, Starobinski M, Jeannet M, Chapuis B. Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 1998;29:301-313.
14. Champlin R, Khouri I, Komblau S, Molidrem J, Giralt S. Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect. Oncology. 1999;13:621-628.
15. Craddock C. Nonmyeloablative stem cell transplants. Curr Opin Hematol. 1999;6:383-387.
16. Xun CQ, McSweeney PA, Boeckh M, Storb RF, Broudy VC, Thompson JA. Successful nonmyeloablative allogeneic hematopoietic stem cell transplant in an acute leukemia patient with chemotherapy-induced marrow aplasia and progressive pulmonary aspergillosis. Blood. 1999;94:3273-3276.
17. Childs RW. Nonmyeloablative allogeneic peripheral blood stem-cell transplantation as immunotherapy for malignant diseases. Cancer J Sci Am. 2000;6:179-187.
18. Spitzer TR. Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism. Oncologist. 2000;5:215-223.
19. Sandmaier BM, McSweeney P, Yu C, Storb R. Nonmyeloablative transplants: preclinical and clinical results. Semin Oncol. 2000;27:78-81.
20. Girait S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531-4536.
21. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
22. Nuckols JD, Rasheed BK, McGlennen RC, et al. Evaluation of an automated technique for assessment of marrow engraftment after allogeneic bone marrow transplantation using a commercially available kit. Am J Clin Pathol. 2000;113:135-140.
23. Mohty M, Faucher C, Vey N, et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow minitransplantation. Bone Marrow Transplant. 2000;26:251-255.